Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Distress, uncertainty, and positive experiences associated with receiving information on personal genomic risk of melanoma.

Smit AK, Newson AJ, Best M, Badcock CA, Butow PN, Kirk J, Dunlop K, Fenton G, Cust AE.

Eur J Hum Genet. 2018 Aug;26(8):1094-1100. doi: 10.1038/s41431-018-0145-z. Epub 2018 Apr 30.

PMID:
29706632
2.

A Pilot Randomized Controlled Trial of the Feasibility, Acceptability, and Impact of Giving Information on Personalized Genomic Risk of Melanoma to the Public.

Smit AK, Espinoza D, Newson AJ, Morton RL, Fenton G, Freeman L, Dunlop K, Butow PN, Law MH, Kimlin MG, Keogh LA, Dobbinson SJ, Kirk J, Kanetsky PA, Mann GJ, Cust AE.

Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):212-221. doi: 10.1158/1055-9965.EPI-16-0395. Epub 2016 Oct 4.

3.

Genetic testing for hereditary melanoma and pancreatic cancer: a longitudinal study of psychological outcome.

Aspinwall LG, Taber JM, Leaf SL, Kohlmann W, Leachman SA.

Psychooncology. 2013 Feb;22(2):276-89. doi: 10.1002/pon.2080. Epub 2011 Oct 7.

PMID:
23382133
4.

Does personalized melanoma genomic risk information trigger conversations about skin cancer prevention and skin examination with family, friends and health professionals?

Smit AK, Keogh LA, Newson AJ, Butow PN, Dunlop K, Morton RL, Kirk J, Espinoza D, Cust AE.

Br J Dermatol. 2017 Sep;177(3):779-790. doi: 10.1111/bjd.15744. Epub 2017 Jul 20.

PMID:
28627002
5.

Exploring the Potential Emotional and Behavioural Impact of Providing Personalised Genomic Risk Information to the Public: A Focus Group Study.

Smit AK, Keogh LA, Newson AJ, Hersch J, Butow P, Cust AE.

Public Health Genomics. 2015;18(5):309-17. doi: 10.1159/000439246. Epub 2015 Sep 22.

PMID:
26390062
6.

Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk.

Aspinwall LG, Stump TK, Taber JM, Drummond DM, Kohlmann W, Champine M, Leachman SA.

Transl Behav Med. 2018 Jan 29;8(1):29-43. doi: 10.1093/tbm/ibx011.

7.

Psychological distress related to BRCA testing in ovarian cancer patients.

Bjørnslett M, Dahl AA, Sørebø Ø, Dørum A.

Fam Cancer. 2015 Dec;14(4):495-504. doi: 10.1007/s10689-015-9811-2.

PMID:
25980896
8.

A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire.

Cella D, Hughes C, Peterman A, Chang CH, Peshkin BN, Schwartz MD, Wenzel L, Lemke A, Marcus AC, Lerman C.

Health Psychol. 2002 Nov;21(6):564-72.

PMID:
12433008
9.

Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease.

Cassidy MR, Roberts JS, Bird TD, Steinbart EJ, Cupples LA, Chen CA, Linnenbringer E, Green RC.

Alzheimers Dement. 2008 Nov;4(6):406-13. doi: 10.1016/j.jalz.2008.04.007.

10.

Psychosocial impact of prognostic genetic testing in the care of uveal melanoma patients: protocol of a controlled prospective clinical observational study.

Erim Y, Scheel J, Breidenstein A, Metz CH, Lohmann D, Friederich HC, Tagay S.

BMC Cancer. 2016 Jul 7;16:408. doi: 10.1186/s12885-016-2479-7.

11.

Predictors of psychological distress among individuals with a strong family history of malignant melanoma.

Kasparian NA, Meiser B, Butow PN, Simpson JM, Mann GJ.

Clin Genet. 2008 Feb;73(2):121-31. doi: 10.1111/j.1399-0004.2007.00949.x. Epub 2007 Dec 28.

PMID:
18177469
12.

The nature and structure of psychological distress in people at high risk for melanoma: a factor analytic study.

Kasparian NA, Sansom-Daly U, McDonald RP, Meiser B, Butow PN, Mann GJ.

Psychooncology. 2012 Aug;21(8):845-56. doi: 10.1002/pon.1976. Epub 2011 May 24.

PMID:
21612004
13.

Disclosure of APOE genotype for risk of Alzheimer's disease.

Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, Eckert SL, Butson M, Sadovnick AD, Quaid KA, Chen C, Cook-Deegan R, Farrer LA; REVEAL Study Group.

N Engl J Med. 2009 Jul 16;361(3):245-54. doi: 10.1056/NEJMoa0809578.

14.

Disclosing individual CDKN2A research results to melanoma survivors: interest, impact, and demands on researchers.

Christensen KD, Roberts JS, Shalowitz DI, Everett JN, Kim SY, Raskin L, Gruber SB.

Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):522-9. doi: 10.1158/1055-9965.EPI-10-1045. Epub 2011 Feb 9.

15.

Implementing an Internet-Delivered Skin Cancer Genetic Testing Intervention to Improve Sun Protection Behavior in a Diverse Population: Protocol for a Randomized Controlled Trial.

Hay JL, Berwick M, Zielaskowski K, White KA, Rodríguez VM, Robers E, Guest DD, Sussman A, Talamantes Y, Schwartz MR, Greb J, Bigney J, Kaphingst KA, Hunley K, Buller DB.

JMIR Res Protoc. 2017 Apr 25;6(4):e52. doi: 10.2196/resprot.7158.

16.

Exploring the emotional and behavioural reactions to receiving personalized melanoma genomic risk information: a qualitative study.

Fenton GL, Smit AK, Keogh L, Cust AE.

Br J Dermatol. 2018 Dec 22. doi: 10.1111/bjd.17582. [Epub ahead of print]

PMID:
30580464
17.

Outcomes of a Randomized Controlled Trial of Genomic Counseling for Patients Receiving Personalized and Actionable Complex Disease Reports.

Sweet K, Sturm AC, Schmidlen T, McElroy J, Scheinfeldt L, Manickam K, Gordon ES, Hovick S, Scott Roberts J, Toland AE, Christman M.

J Genet Couns. 2017 Oct;26(5):980-998. doi: 10.1007/s10897-017-0073-z. Epub 2017 Mar 27.

18.

Hereditary melanoma and predictive genetic testing: why not?

Riedijk SR, de Snoo FA, van Dijk S, Bergman W, van Haeringen A, Silberg S, van Elderen TM, Tibben A.

Psychooncology. 2005 Sep;14(9):738-45.

PMID:
15744786
19.

Psychoeducational Intervention to Reduce Fear of Cancer Recurrence in People at High Risk of Developing Another Primary Melanoma: Results of a Randomized Controlled Trial.

Dieng M, Butow PN, Costa DS, Morton RL, Menzies SW, Mireskandari S, Tesson S, Mann GJ, Cust AE, Kasparian NA.

J Clin Oncol. 2016 Dec 20;34(36):4405-4414. Epub 2016 Oct 28.

PMID:
27998215
20.

Perceptions of genetic research and testing among members of families with an increased risk of malignant melanoma.

Bränström R, Kasparian NA, Affleck P, Tibben A, Chang YM, Azizi E, Baron-Epel O, Bergman W, Chan M, Davies J, Ingvar C, Kanetsky PA, van Leeuwen E, Olsson H, Gruis NA, Brandberg Y, Newton-Bishop J.

Eur J Cancer. 2012 Nov;48(16):3052-62. doi: 10.1016/j.ejca.2012.05.017. Epub 2012 Jun 21.

PMID:
22726816

Supplemental Content

Support Center